HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

Executive Summary

A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.

You may also be interested in...



US Consumer Health 2020 News: ’60 Minutes’ Probiotic Dip Tops Switches, Monograph, Pandemic

Supplement industry’s bullseye on “60 Minutes” after its June segment critical of probiotic health benefits generated the most reads for a US consumer health and overall for HBW Insight articles in 2020. Articles about COVID-19 enforcement actions weren’t as widely read as coverage of FDA’s reorganization in its OTC drug offices and its approvals of additional ingredients to be available OTC.

US Probiotics Market Stirs With Chobani Beverages, Danone, Sofar And Plexus Blends For Kids

Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.

US Homeopathic Firm’s Failure To Test Supplies, Lax Approach On Recalls Lead To Warning

Although Washington Homeopathic informed FDA it recalled homeopathics manufactured by a supplier on import alert and would recall “high risk” tinctures, it would allow its customers to decide whether to return other products also identified as potentially adulterated.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel